Cancer Therapeutics CRC Pty Ltd Product Pipeline Review 2012


#146236

40pages

Global Markets Direct

$ 1500

In Stock


Cancer Therapeutics CRC Pty Ltd Product Pipeline Review 2012

Global Market Directs pharmaceuticals report, Cancer Therapeutics CRC Pty Ltd Product Pipeline Review 2012 provides data on the Cancer Therapeutics CRC Pty Ltds research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects. 

This report is built using data and information sourced from Global Markets Directs proprietary databases, Cancer Therapeutics CRC Pty Ltds corporate website, SEC filings, investor presentations and featured press releases, both from Cancer Therapeutics CRC Pty Ltd and industry-specific third party sources, put together by Global Markets Directs team. 

Scope

  • Cancer Therapeutics CRC Pty Ltd Brief Cancer Therapeutics CRC Pty Ltd overview including business description, key information and facts, and its locations and subsidiaries.
  • Review of current pipeline of Cancer Therapeutics CRC Pty Ltd human therapeutic division.
  • Overview of pipeline therapeutics across various therapy areas.
  • Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
  • Product profiles for late stage and clinical stage products of Cancer Therapeutics CRC Pty Ltd with complete description of the products developmental history, mechanism of action, therapeutic class, target and major milestones. 
  • Recent updates of the Cancer Therapeutics CRC Pty Ltds pipeline in the last quarter. 
  • Key discontinued and dormant projects. 
  • Latest news and deals relating to the products.

Reasons to buy

  • Evaluate Cancer Therapeutics CRC Pty Ltds strategic position with total access to detailed information on its product pipeline. 
  • Assess the growth potential of Cancer Therapeutics CRC Pty Ltd in its therapy areas of focus. 
  • Identify new drug targets and therapeutic classes in the Cancer Therapeutics CRC Pty Ltds R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas. 
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps. 
  • Exploit collaboration and partnership opportunities with Cancer Therapeutics CRC Pty Ltd.
  • Avoid Intellectual Property Rights related issues. 
  • Explore the dormant and discontinued projects of Cancer Therapeutics CRC Pty Ltd and identify potential opportunities in those areas.
Table of Contents

Table of Contents 2

List of Tables 4
List of Figures 4
Cancer Therapeutics CRC Pty Ltd Snapshot 5
Cancer Therapeutics CRC Pty Ltd Overview 5
Key Information 5
Key Facts 5
Cancer Therapeutics CRC Pty Ltd Research and Development Overview 6
Key Therapeutic Areas 6
Cancer Therapeutics CRC Pty Ltd Pipeline Review 9
Pipeline Products by Stage of Development 9
Pipeline Products Monotherapy 10
Pipeline Products Combination Treatment Modalities 11
Cancer Therapeutics CRC Pty Ltd Pipeline Products Glance 12
Cancer Therapeutics CRC Pty Ltd Early Stage Pipeline Products 12
Pre-Clinical Products/Combination Treatment Modalities 12
Discovery Products/Combination Treatment Modalities 13
Cancer Therapeutics CRC Pty Ltd Drug Profiles 14
CTX-0294945 + Avastin 14
Product Description 14
Mechanism of Action 14
R&D Progress 14
Drug Targeting cFMS 16
Product Description 16
Mechanism of Action 16
R&D Progress 16
Drug Targeting E6AP 17
Product Description 17
Mechanism of Action 17
R&D Progress 17
Drug Targeting FAK 18
Product Description 18
Mechanism of Action 18
R&D Progress 18
Drug Targeting FAK, FLT3 And VEGFR3 19
Product Description 19
Mechanism of Action 19
R&D Progress 19
Drug Targeting ICMT 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
Drug Targeting PRMT5 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
Drug Targeting VEGFR3 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
Drug Targetiong SIAH 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
Program Targeting Cancer 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
Cancer Therapeutics CRC Pty Ltd Pipeline Analysis 25
Cancer Therapeutics CRC Pty Ltd Pipeline Products by Therapeutic Class 25
Cancer Therapeutics CRC Pty Ltd Pipeline Products By Mechanism of Action 26
Cancer Therapeutics CRC Pty Ltd - Dormant Projects 27
Cancer Therapeutics CRC Pty Ltd Locations And Subsidiaries 28
Head Office 28
Cancer Therapeutics CRC Pty Ltd, Recent Developments 29
Cancer Therapeutics CRC Pty Ltd- Press Release 29
Jul 05, 2012: Cancer Therapeutics Reveals Proof Of Concept For Breast Cancer Drug 29
Apr 03, 2012: Cancer Therapeutics Presents Positive Preclinical Results Of CTX-0294945 At AACR Annual Meeting 30
Apr 03, 2012: Cancer Therapeutics Reports Positive Preclinical Results Of Cancer Drug CTX-0294945 30
Jun 11, 2009: Novation and Cancer Therapeutics Establish Collaboration For the Discovery and Development of New Cancer Therapies 31
May 26, 2009: Cytopia Cancer Program Reaches Important Milestone At Cancer Therapeutics CRC 31
Financial Deals Landscape 32
Cancer Therapeutics CRC Pty Ltd, Deals Summary 32
Cancer Therapeutics CRC Pty Ltd, Pharmaceuticals & Healthcare, Deal Details 33
Partnerships 33
Cancer Therapeutics Enters Into Research Agreement With Duke University 33
Novation Pharma Enters Into Collaboration Agreement With Cancer Therapeutics 34
Cytopia Enters Into Collaboration Agreement With Cancer Therapeutics 35
Cancer Therapeutics Enters Into Co-Development Agreement With Queensland Institute 36
Licensing Agreements 37
Cancer Research Technology Enters Into Licensing Agreement With Cancer Therapeutics For FAK Inhibitor Portfolio 37

Appendix 39
Methodology 39
Coverage 39
Secondary Research 39
Primary Research 39
Expert Panel Validation 39
Contact Us 40
Disclaimer 40

Cancer Therapeutics CRC Pty Ltd, Key Information 5
Cancer Therapeutics CRC Pty Ltd, Key Facts 5
Cancer Therapeutics CRC Pty Ltd Pipeline by Indication, 2012 7
Cancer Therapeutics CRC Pty Ltd Pipeline by Stage of Development, 2012 9
Cancer Therapeutics CRC Pty Ltd Monotherapy Products in Pipeline, 2012 10
Cancer Therapeutics CRC Pty Ltd Combination Treatment Modalities in Pipeline, 2012 11
Cancer Therapeutics CRC Pty Ltd Pre-Clinical, 2012 12
Cancer Therapeutics CRC Pty Ltd Discovery, 2012 13
Cancer Therapeutics CRC Pty Ltd Pipeline By Therapeutic Class, 2012 25
Cancer Therapeutics CRC Pty Ltd Pipeline Products By Mechanism of Action, 2012 26
Cancer Therapeutics CRC Pty Ltd - Dormant Developmental Projects,2012 27
Cancer Therapeutics CRC Pty Ltd, Deals Summary 32
Cancer Therapeutics Enters Into Research Agreement With Duke University 33
Novation Pharma Enters Into Collaboration Agreement With Cancer Therapeutics 34
Cytopia Enters Into Collaboration Agreement With Cancer Therapeutics 35
Cancer Therapeutics Enters Into Co-Development Agreement With Queensland Institute 36
Cancer Research Technology Enters Into Licensing Agreement With Cancer Therapeutics For FAK Inhibitor Portfolio 37
Cancer Therapeutics CRC Pty Ltd Pipeline by Indication, 2012 7
Cancer Therapeutics CRC Pty Ltd Pipeline by Stage of Development, 2012 9
Cancer Therapeutics CRC Pty Ltd Monotherapy Products in Pipeline, 2012 10
Cancer Therapeutics CRC Pty Ltd Combination Treatment Modalities in Pipeline, 2012 11
Cancer Therapeutics CRC Pty Ltd - Pipeline Products By Mechanism of Action, 2012 26